Satietrol Suppresses Appetite

Satietrol Suppresses Appetite

MATAWAN, N.J.The weight loss ingredient Satietrol® (fromPacificHealth Laboratories Inc.) produces a 20-percent reduction in food intake,according to results of a new proprietary trial. The ingredient is designed tosuppress appetite by activating the cholecystokinin (CCK) hormone, whichprolongs satiety.

In the double blind, placebo-controlled study, researchers administeredSatietrol as a soft chewable tablet or placebo to overweight subjects with anaverage body mass index (BMI) of 28, prior to an open-ended meal. Individualsgiven Satietrol demonstrated a 20-percent reduction in caloric intake comparedto the placebo group.

Results from this latest clinical study provide additional evidence on theeffectiveness of our improved formulation, said Robert Portman, chief executive officer (CEO) of PacificHealth Labs(www.pacifichealthlabs.com). We now have completed three studies with theimproved technology. All studies have been positive and the average caloric reduction in the threestudies ranges from 10 to 20 percent. We have also instituted two clinical trials with the new form: a 12-weekstudy measuring weight loss in obese individuals and the effects of the new formon patients with Type II diabetes. Our research goal in weight loss has not only been to develop an effectiveand safe appetite suppressive agent but also to incorporate it into aconsumer-friendly form. The soft chewable tablet is an elegant delivery systemthat will be initially available in a chocolate-covered chewable tablet.We mayalso introduce the product as an 8-oz. beverage taken before a meal.